PubMed:32886791
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 51-63 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
T2 | 287-299 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
T3 | 396-408 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
T4 | 450-463 | Body_part | denotes | cell surfaces | http://purl.org/sig/ont/fma/fma67653 |
T5 | 450-454 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 34-42 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 111-119 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 151-159 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 323-332 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 171-172 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 204-209 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T3 | 444-454 | http://purl.obolibrary.org/obo/CLO_0053065 | denotes | human cell |
T4 | 771-772 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 51-63 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
T2 | 287-299 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
T3 | 396-408 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
T4 | 409-420 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T5 | 695-704 | Chemical | denotes | N-glycans | http://purl.obolibrary.org/obo/CHEBI_59520 |
T6 | 697-704 | Chemical | denotes | glycans | http://purl.obolibrary.org/obo/CHEBI_18154 |
T7 | 730-738 | Chemical | denotes | LacdiNAc | http://purl.obolibrary.org/obo/CHEBI_61190 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 601-614 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
T2 | 788-803 | http://purl.obolibrary.org/obo/GO_0006493 | denotes | O-glycosylation |
T3 | 790-803 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-88 | Sentence | denotes | Site-specific characterisation of SARS-CoV-2 spike glycoprotein receptor binding domain. |
T2 | 89-255 | Sentence | denotes | The novel coronavirus SARS-CoV-2, the infective agent causing COVID-19, is having a global impact both in terms of human disease as well as socially and economically. |
T3 | 256-464 | Sentence | denotes | Its heavily glycosylated spike glycoprotein is fundamental for the infection process, via its receptor binding domains interaction with the glycoprotein angiotensin converting enzyme 2 on human cell surfaces. |
T4 | 465-650 | Sentence | denotes | We therefore utilized an integrated glycomic and glycoproteomic analytical strategy to characterise both N- and O- glycan site specific glycosylation within the receptor binding domain. |
T5 | 651-812 | Sentence | denotes | We demonstrate the presence of complex type N-glycans with unusual fucosylated LacdiNAc at both sites N331 and N343 and a single site of O-glycosylation on T323. |
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 730-738 | Glycan_Motif | denotes | LacdiNAc | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G31736BK|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00057MO |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-88 | Sentence | denotes | Site-specific characterisation of SARS-CoV-2 spike glycoprotein receptor binding domain. |
T2 | 89-255 | Sentence | denotes | The novel coronavirus SARS-CoV-2, the infective agent causing COVID-19, is having a global impact both in terms of human disease as well as socially and economically. |
T3 | 256-464 | Sentence | denotes | Its heavily glycosylated spike glycoprotein is fundamental for the infection process, via its receptor binding domains interaction with the glycoprotein angiotensin converting enzyme 2 on human cell surfaces. |
T4 | 465-650 | Sentence | denotes | We therefore utilized an integrated glycomic and glycoproteomic analytical strategy to characterise both N- and O- glycan site specific glycosylation within the receptor binding domain. |
T5 | 651-812 | Sentence | denotes | We demonstrate the presence of complex type N-glycans with unusual fucosylated LacdiNAc at both sites N331 and N343 and a single site of O-glycosylation on T323. |
T1 | 0-88 | Sentence | denotes | Site-specific characterisation of SARS-CoV-2 spike glycoprotein receptor binding domain. |
T2 | 89-255 | Sentence | denotes | The novel coronavirus SARS-CoV-2, the infective agent causing COVID-19, is having a global impact both in terms of human disease as well as socially and economically. |
T3 | 256-464 | Sentence | denotes | Its heavily glycosylated spike glycoprotein is fundamental for the infection process, via its receptor binding domains interaction with the glycoprotein angiotensin converting enzyme 2 on human cell surfaces. |
T4 | 465-650 | Sentence | denotes | We therefore utilized an integrated glycomic and glycoproteomic analytical strategy to characterise both N- and O- glycan site specific glycosylation within the receptor binding domain. |
T5 | 651-812 | Sentence | denotes | We demonstrate the presence of complex type N-glycans with unusual fucosylated LacdiNAc at both sites N331 and N343 and a single site of O-glycosylation on T323. |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 730-738 | https://glytoucan.org/Structures/Glycans/G00057MO | denotes | LacdiNAc |
T2 | 730-738 | https://glytoucan.org/Structures/Glycans/G31736BK | denotes | LacdiNAc |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 34-44 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 111-121 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 151-159 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 323-332 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 34-42 | OrganismTaxon | denotes | SARS-CoV | 694009 |
T2 | 111-119 | OrganismTaxon | denotes | SARS-CoV | 694009 |
T3 | 204-209 | OrganismTaxon | denotes | human | 9606 |
T4 | 444-449 | OrganismTaxon | denotes | human | 9606 |